Delivery Order SPE2DB24D2205-SPE2DB25FEDCH
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,575.75 for IMBRUVICA 140 mg tablets (28-count supply) on August 28, 2025, with completion scheduled for September 19, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, received a $8,116.87 delivery order award from the Defense Logistics Agency on September 10, 2025, for IMBRUVICA 140 mg capsules (90-count supply). The contract operates under firm fixed-price terms with an ultimate completion date of October 1, 2025, and was awarded competitively with no set-aside designation. This delivery order is a child contract issued against AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a $50,797.65 delivery order by the Defense Logistics Agency on May 12, 2025, for the supply of IMBRUVICA 420 mg tablets (28-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of June 3, 2025. The award represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order valued at $7,575.75 to AmerisourceBergen Drug Corp for the supply of Imbruvica 140 mg tablets (28-count) with a firm fixed price structure. The contract, which was competitively awarded without set-aside designation, is scheduled for completion by October 14, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $37,878.75 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 420 mg tablets (28-count units) on August 14, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp for IMBRUVICA 70 mg capsules (28-count) on August 28, 2025, with a completion date of September 19, 2025. This non-set-aside contract uses firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $7,575.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Imbruvica 70 mg capsules (28-count packaging) with a completion date of June 24, 2025. This non-set-aside, competitively awarded contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count) with a ceiling value of $76,839.82. This firm fixed-price delivery order, with an ultimate completion date of September 9, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Imbruvica 420 mg tablets (28-count packaging) with a contract ceiling value of $15,151.52. This is a firm fixed-price delivery order with an ultimate completion date of October 7, 2025, representing a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The award was competitively awarded with no set-aside designation, and performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,575.75 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 420 mg tablets (28-count units) with delivery to Conshohocken, Pennsylvania. This contract, awarded on August 4, 2025, utilizes a firm fixed-price structure with an ultimate completion date of August 25, 2025. The award was made without a set-aside designation, indicating it was competitively awarded among qualified vendors. This delivery order represents a...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEDCHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,575.75 to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 140 mg tablets (28-count packaging) with a completion deadline of June 24, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing critical medical procurement support to federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The company maintains an extensive portfolio of federal contract awards covering a broad spectrum of pharmaceutical products and medical supplies through the DLA Medical Supply Chain. This delivery order for IMBRUVICA, a specialty oncology medication, exemplifies the company's role in supplying brand-name and specialized pharmaceuticals to support military medical requirements worldwide. The contract maintains firm fixed pricing consistent with DLA's standard delivery order practices under its established prime vendor agreements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 6/2/25 |